Potential targeted therapy for liver fluke associated cholangiocarcinoma
- 10 January 2014
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 21 (6) , 362-370
Abstract
Biliary tree cancer or cholangiocarcinoma (CCA) is an unusual subtype of liver cancer with exceptionally poor prognosis. Lack of specific symptoms and availability of early diagnostic markers account for late diagnosis of CCA. Surgical treatment is a gold standard choice but few patients are candidates and local recurrence after surgery is high. Benefit of systemic chemotherapy is limited; hence, better treatment options are required. The differences in etiology, anatomical positions and pathology make it difficult to generalize all CCA subtypes for a single treatment regimen. Herein, we review the uniqueness of molecular profiling identified by multiple approaches, for example, serial analysis of gene expression, exome sequencing, transcriptomics/proteomics profiles, protein kinase profile, etc., that provide the opportunity for treatment of liver fluke‐associated CCA. Anti‐inflammatory, immunomodulator/immunosuppressor, epidermal growth factor receptor or platelet‐derived growth factor receptor inhibitors, multi‐targeted tyrosine kinase inhibitor, IL6 antagonist, nuclear factor‐κB inhibitor, histone modulator, proteasome inhibitor as well as specific inhibitors suggested from various study approaches, such as MetAP2 inhibitor, 1,25(OH)2D3 and cyclosporine A are suggested in this review for the treatments of this specific CCA subtype. This might provide an alternative treatment option for CCA patients; however, clinical trials in this specific CCA group are required.Keywords
This publication has 82 references indexed in Scilit:
- Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinomaMolecular Cancer, 2011
- CpG-island methylation study of liver fluke-related cholangiocarcinomaBritish Journal of Cancer, 2011
- Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyteParasitology International, 2010
- Personalized Medicine in Non–Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor–Targeted Therapy?Journal of Clinical Oncology, 2010
- Circulating CD14+CD16+ monocyte levels predict tissue invasive character of cholangiocarcinomaClinical and Experimental Immunology, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- Myristoylated alanine‐rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C‐dependent pathwayCancer Science, 2010
- Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2†Hepatology, 2009
- Advanced Periductal Fibrosis from Infection with the Carcinogenic Human Liver Fluke Opisthorchis viverrini Correlates with Elevated Levels of Interleukin-6† ‡Hepatology, 2009
- Intrahepatic CholangiocarcinomaAnnals of Surgery, 2008